Frontotemporal Dementia

Neurologic Clinics

Volumn 35, Issue 2, 2017, Pages 339-374

  Olney, Nicholas T ^a   Spina, Salvatore ^a   Miller, Bruce L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Corticobasal syndrome (CBS); Frontotemporal dementia (FTD); Motor neuron disease; Nonfluent PPA; Primary progressive aphasia; Progressive supranuclear palsy (PSP); Semantic PPA

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MEMANTINE; OXYTOCIN; PROGRANULIN; PROTEASOME; TAR DNA BINDING PROTEIN; TAU PROTEIN; TRAZODONE; UBIQUITIN;

ARGYROPHILIC GRAIN DISEASE; CHROMOSOME 9; CORTICOBASAL DEGENERATION; EXECUTIVE FUNCTION; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; GENE MUTATION; GLOBULAR GLIAL TAUOPATHY; HUMAN; KINESIOTHERAPY; MOTOR NEURON DISEASE; NEUROPATHOLOGY; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PICK PRESENILE DEMENTIA; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; PROGRESSIVE NONFLUENT APHASIA; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN FUNCTION; REVIEW; TAUOPATHY; BRAIN; HISTORY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

BRAIN; FRONTOTEMPORAL DEMENTIA; HISTORY, 20TH CENTURY; HUMANS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 85028188850     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2017.01.008     Document Type: Review

References (240)

1. 1 Pick, A., Uber die Beziehungen der Senilen Hirnatrophie zur Aphasie. Prager Medizinische Wochenschrift 17 (1892), 165–167.
2. 2 Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., et al. Classification of primary progressive aphasia and its variants. Neurology 76:11 (2011), 1006–1014.
3. 3 Alzheimer, A., Uber Eigenartige Krankheitsfalle des Spateren Alters. Z Gesamte Neruol Psychiatr 4 (1911), 356–385.
4. 4 Thibodeau, M.P., Miller, B.L., ‘Limits and current knowledge of Pick's disease: its differential diagnosis'. A translation of the 1957 Delay, Brion, Escourolle article. Neurocase 19:5 (2013), 417–422.
5. 5 Rosen, H.J., Lengenfelder, J., Miller, B., Frontotemporal dementia. Neurol Clin 18:4 (2000), 979–992.
6. 6 Miller, B.L., Frontotemporal dementia. 2014, Oxford University Press, New York.
7. 7 Jellinger, K.A., The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathol 113:4 (2007), 349–388.
8. 8 Roman, G., Vascular dementia: a historical background. Int Psychogeriatr 15:Suppl 1 (2003), 11–13.
9. 9 Constantinidis, J., Richard, J., Tissot, R., Pick's disease: histological and clinical correlations. Eur Neurol 11 (1974), 208–217.
10. 10 Ryan, N.S., Rossor, M.N., Fox, N.C., Alzheimer's disease in the 100 years since Alzheimer's death. Brain 138:Pt 12 (2015), 3816–3821.
11. 11 Katzman, R., Editorial: the prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol 33:4 (1976), 217–218.
12. 12 Brun, A., Frontal lobe degeneration of non-Alzheimer type revisited. Dementia 4 (1993), 126–131.
13. 13 Ingvar, D.H., Gustafson, L., Regional cerebral blood flow in organic dementia with early onset. Acta Neurol Scand, 46(Suppl 43), 1970, 42+.
14. 14 Mesulam, M.M., Slowly progressive aphasia without generalized dementia. Ann Neurol 11:6 (1982), 592–598.
15. 15 Mesulam, M.M., Primary progressive aphasia. Ann Neurol 49:4 (2001), 425–432.
16. 16 Snowden, J.S., Goulding, P.J., Neary, D., Semantic dementia: a form of circumscribed cerebral atrophy. Behav Neurol 2 (1989), 167–182.
17. 17 Edwards-Lee, T., Miller, B.L., Benson, D.F., et al. The temporal variant of frontotemporal dementia. Brain 120:Pt 6 (1997), 1027–1040.
18. 18 Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatr 57:4 (1994), 416–418.
19. 19 Neary, D., Snowden, J.S., Gustafson, L., et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51:6 (1998), 1546–1554.
20. 20 Rascovsky, K., Hodges, J.R., Knopman, D., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:Pt 9 (2011), 2456–2477.
21. 21 Coyle-Gilchrist, I.T., Dick, K.M., Patterson, K., et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 86:18 (2016), 1736–1743.
22. 22 Knopman, D.S., Roberts, R.O., Estimating the number of persons with frontotemporal lobar degeneration in the US population. J Mol Neurosci 45:3 (2011), 330–335.
23. 23 Hodges, J.R., Davies, R., Xuereb, J., et al. Survival in frontotemporal dementia. Neurology 61:3 (2003), 349–354.
24. 24 Snowden, J.S., Neary, D., Mann, D.M., Frontotemporal dementia. Br J Psychiatry 180 (2002), 140–143.
25. 25 Hogan, D.B., Jette, N., Fiest, K.M., et al. The prevalence and incidence of frontotemporal dementia: a systematic review. Can J Neurol Sci 43:Suppl 1 (2016), S96–S109.
26. 26 Onyike, C.U., Diehl-Schmid, J., The epidemiology of frontotemporal dementia. Int Rev Psychiatry 25:2 (2013), 130–137.
27. 27 Lanata, S.C., Miller, B.L., The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry. J Neurol Neurosurg Psychiatr 87:5 (2016), 501–511.
28. 28 Woolley, J.D., Khan, B.K., Murthy, N.K., et al. The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry 72:2 (2011), 126–133.
29. 29 Rosen, H.J., Allison, S.C., Schauer, G.F., et al. Neuroanatomical correlates of behavioural disorders in dementia. Brain 128:Pt 11 (2005), 2612–2625.
30. 30 Seeley, W.W., Crawford, R., Rascovsky, K., et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 65:2 (2008), 249–255.
31. 31 Seeley, W.W., Carlin, D.A., Allman, J.M., et al. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol 60:6 (2006), 660–667.
32. 32 Seeley, W.W., Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. Curr Opin Neurol 21:6 (2008), 701–707.
33. 33 Schroeter, M.L., Raczka, K., Neumann, J., et al. Neural networks in frontotemporal dementia–a meta-analysis. Neurobiol Aging 29:3 (2008), 418–426.
34. 34 Seeley, W.W., Menon, V., Schatzberg, A.F., et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 27:9 (2007), 2349–2356.
35. 35 Seeley, W.W., Zhou, J., Kim, E.J., Frontotemporal dementia: what can the behavioral variant teach us about human brain organization?. Neuroscientist 18:4 (2012), 373–385.
36. 36 Kfoury, N., Holmes, B.B., Jiang, H., et al. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 287:23 (2012), 19440–19451.
37. 37 Walker, L.C., Jucker, M., Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci 38 (2015), 87–103.
38. 38 Kramer, J.H., Jurik, J., Sha, S.J., et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 16:4 (2003), 211–218.
39. 39 Tekin, S., Cummings, J.L., Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 53:2 (2002), 647–654.
40. 40 Tranel, D., Bechara, A., Denburg, N.L., Asymmetric functional roles of right and left ventromedial prefrontal cortices in social conduct, decision-making, and emotional processing. Cortex 38:4 (2002), 589–612.
41. 41 Diehl-Schmid, J., Perneczky, R., Koch, J., et al. Guilty by suspicion? Criminal behavior in frontotemporal lobar degeneration. Cogn Behav Neurol 26:2 (2013), 73–77.
42. 42 Liljegren, M., Naasan, G., Temlett, J., et al. Criminal behavior in frontotemporal dementia and Alzheimer disease. JAMA Neurol 72:3 (2015), 295–300.
43. 43 Rankin, K.P., Baldwin, E., Pace-Savitsky, C., et al. Self awareness and personality change in dementia. J Neurol Neurosurg Psychiatr 76:5 (2005), 632–639.
44. 44 Chow, T.W., Binns, M.A., Cummings, J.L., et al. Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type. Arch Neurol 66:7 (2009), 888–893.
45. 45 Merrilees, J., Hubbard, E., Mastick, J., et al. Rest-activity and behavioral disruption in a patient with frontotemporal dementia. Neurocase 15:6 (2009), 515–526.
46. 46 Holroyd, C.B., Yeung, N., Motivation of extended behaviors by anterior cingulate cortex. Trends Cogn Sci 16:2 (2012), 122–128.
47. 47 Rosen, H.J., Gorno-Tempini, M.L., Goldman, W.P., et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 58:2 (2002), 198–208.
48. 48 Mendez, M.F., Shapira, J.S., Loss of emotional insight in behavioral variant frontotemporal dementia or “frontal anosodiaphoria”. Conscious Cogn 20:4 (2011), 1690–1696.
49. 49 Rankin, K.P., Gorno-Tempini, M.L., Allison, S.C., et al. Structural anatomy of empathy in neurodegenerative disease. Brain 129:Pt 11 (2006), 2945–2956.
50. 50 Ames, D., Cummings, J.L., Wirshing, W.C., et al. Repetitive and compulsive behavior in frontal lobe degenerations. J Neuropsychiatry Clin Neurosci 6:2 (1994), 100–113.
51. 51 Josephs, K.A., Whitwell, J.L., Jack, C.R. Jr., Anatomic correlates of stereotypies in frontotemporal lobar degeneration. Neurobiol Aging 29:12 (2008), 1859–1863.
52. 52 Perry, D.C., Whitwell, J.L., Boeve, B.F., et al. Voxel-based morphometry in patients with obsessive-compulsive behaviors in behavioral variant frontotemporal dementia. Eur J Neurol 19:6 (2012), 911–917.
53. 53 Rosso, S.M., Roks, G., Stevens, M., et al. Complex compulsive behaviour in the temporal variant of frontotemporal dementia. J Neurol 248:11 (2001), 965–970.
54. 54 Miller, B.L., Darby, A.L., Swartz, J.R., et al. Dietary changes, compulsions and sexual behavior in frontotemporal degeneration. Dementia 6:4 (1995), 195–199.
55. 55 Woolley, J.D., Gorno-Tempini, M.L., Seeley, W.W., et al. Binge eating is associated with right orbitofrontal-insular-striatal atrophy in frontotemporal dementia. Neurology 69:14 (2007), 1424–1433.
56. 56 Whitwell, J.L., Sampson, E.L., Loy, C.T., et al. VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. Neuroimage 35:1 (2007), 207–213.
57. 57 Piguet, O., Eating disturbance in behavioural-variant frontotemporal dementia. J Mol Neurosci 45:3 (2011), 589–593.
58. 58 Gregory, C.A., Serra-Mestres, J., Hodges, J.R., Early diagnosis of the frontal variant of frontotemporal dementia: how sensitive are standard neuroimaging and neuropsychologic tests?. Neuropsychiatry Neuropsychol Behav Neurol 12:2 (1999), 128–135.
59. 59 Kipps, C.M., Hodges, J.R., Hornberger, M., Nonprogressive behavioural frontotemporal dementia: recent developments and clinical implications of the ‘bvFTD phenocopy syndrome'. Curr Opin Neurol 23:6 (2010), 628–632.
60. 60 Khan, B.K., Yokoyama, J.S., Takada, L.T., et al. Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatr 83:4 (2012), 358–364.
61. 61 Ranasinghe, K.G., Rankin, K.P., Lobach, I.V., et al. Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology 86:7 (2016), 600–610.
62. 62 Suarez, J., Tartaglia, M.C., Vitali, P., et al. Characterizing radiology reports in patients with frontotemporal dementia. Neurology 73:13 (2009), 1073–1074.
63. 63 Mesulam, M.M., Primary progressive aphasia: differentiation from Alzheimer's disease. Ann Neurol 37 (1987), 1448–1553.
64. 64 Gorno-Tempini, M.L., Dronkers, N.F., Rankin, K.P., et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 55:3 (2004), 335–346.
65. 65 Mesulam, M., Wicklund, A., Johnson, N., et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 63:6 (2008), 709–719.
66. 66 Rabinovici, G.D., Jagust, W.J., Furst, A.J., et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 64:4 (2008), 388–401.
67. 67 Seeley, W.W., Bauer, A.M., Miller, B.L., et al. The natural history of temporal variant frontotemporal dementia. Neurology 64:8 (2005), 1384–1390.
68. 68 Hodges, J.R., Mitchell, J., Dawson, K., et al. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain 133:Pt 1 (2010), 300–306.
69. 69 Flanagan, E.P., Baker, M.C., Perkerson, R.B., et al. Dominant frontotemporal dementia mutations in 140 cases of primary progressive aphasia and speech apraxia. Dement Geriatr Cogn Disord 39:5–6 (2015), 281–286.
70. 70 Goldman, J.S., Farmer, J.M., Wood, E.M., et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65:11 (2005), 1817–1819.
71. 71 Hodges, J.R., Patterson, K., Ward, R., et al. The differentiation of semantic dementia and frontal lobe dementia (temporal and frontal variants of frontotemporal dementia) from early Alzheimer's disease: a comparative neuropsychological study. Neuropsychology 13:1 (1999), 31–40.
72. 72 Miller, B.L., Chang, L., Mena, I., et al. Progressive right frontotemporal degeneration: clinical, neuropsychological and SPECT characteristics. Dementia 4:3–4 (1993), 204–213.
73. 73 Rosen, H.J., Perry, R.J., Murphy, J., et al. Emotion comprehension in the temporal variant of frontotemporal dementia. Brain 125:Pt 10 (2002), 2286–2295.
74. 74 Miller, B.L., Boone, K., Cummings, J.L., et al. Functional correlates of musical and visual ability in frontotemporal dementia. Br J Psychiatry 176 (2000), 458–463.
75. 75 Miller, B.L., Cummings, J., Mishkin, F., et al. Emergence of artistic talent in frontotemporal dementia. Neurology 51:4 (1998), 978–982.
76. 76 Miller, B.L., Ponton, M., Benson, D.F., et al. Enhanced artistic creativity with temporal lobe degeneration [letter]. Lancet 348:9043 (1996), 1744–1745.
77. 77 Liu, A., Werner, K., Roy, S., et al. A case study of an emerging visual artist with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurocase 15:3 (2009), 235–247.
78. 78 Rohrer, J.D., Rosen, H.J., Neuroimaging in frontotemporal dementia. Int Rev Psychiatry 25:2 (2013), 221–229.
79. 79 Ogar, J., Willock, S., Baldo, J., et al. Clinical and anatomical correlates of apraxia of speech. Brain Lang 97:3 (2006), 343–350.
80. 80 Gorno-Tempini, M.L., Ogar, J.M., Brambati, S.M., et al. Anatomical correlates of early mutism in progressive nonfluent aphasia. Neurology 67:10 (2006), 1849–1851.
81. 81 Lomen-Hoerth, C., Anderson, T., Miller, B., The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59:7 (2002), 1077–1079.
82. 82 McGeer, P.L., Schwab, C., McGeer, E.G., et al. Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Neurology 49:2 (1997), 400–409.
83. 83 Lomen-Hoerth, C., Clinical phenomenology and neuroimaging correlates in ALS-FTD. J Mol Neurosci 45:3 (2011), 656–662.
84. 84 Geevasinga, N., Loy, C.T., Menon, P., et al. Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: a systematic review using individual patient data. Clin Neurophysiol 127:7 (2016), 2684–2691.
85. 85 Brooks, B.R., El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci 124:Suppl (1994), 96–107.
86. 86 Carvalho, M.D., Swash, M., Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 10:1 (2009), 53–57.
87. 87 Olney, R.K., Murphy, J., Forshew, D., et al. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 65:11 (2005), 1774–1777.
88. 88 Mackenzie, I.R., Feldman, H.H., Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol 64:8 (2005), 730–739.
89. 89 Arai, T., Hasegawa, M., Akiyama, H., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:3 (2006), 602–611.
90. 90 Mackenzie, I.R., Neumann, M., Baborie, A., et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122:1 (2011), 111–113.
91. 91 Neumann, M., Sampathu, D.M., Kwong, L.K., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:5796 (2006), 130–133.
92. 92 Kwiatkowski, T.J. Jr., Bosco, D.A., Leclerc, A.L., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323:5918 (2009), 1205–1208.
93. 93 Neumann, M., Bentmann, E., Dormann, D., et al. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134:Pt 9 (2011), 2595–2609.
94. 94 Vance, C., Rogelj, B., Hortobagyi, T., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323:5918 (2009), 1208–1211.
95. 95 Mackenzie, I.R., Rademakers, R., Neumann, M., TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 9:10 (2010), 995–1007.
96. 96 Neumann, M., Rademakers, R., Roeber, S., et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132:Pt 11 (2009), 2922–2931.
97. 97 Snowden, J.S., Hu, Q., Rollinson, S., et al. The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. Acta Neuropathol 122:1 (2011), 99–110.
98. 98 Urwin, H., Josephs, K.A., Rohrer, J.D., et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 120:1 (2010), 33–41.
99. 99 Hosler, B.A., Siddique, T., Sapp, P.C., et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 284:13 (2000), 1664–1669.
100. 100 DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:2 (2011), 245–256.
101. 101 Renton, A.E., Majounie, E., Waite, A., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:2 (2011), 257–268.
102. 102 Rebeiz, J.J., Kolodny, E.H., Richardson, E.P. Jr., Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18:1 (1968), 20–33.
103. 103 Armstrong, M.J., Litvan, I., Lang, A.E., et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80:5 (2013), 496–503.
104. 104 Boeve, B.F., Maraganore, D.M., Parisi, J.E., et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53:4 (1999), 795–800.
105. 105 Josephs, K.A., Petersen, R.C., Knopman, D.S., et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 66:1 (2006), 41–48.
106. 106 Lee, S.E., Rabinovici, G.D., Mayo, M.C., et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 70:2 (2011), 327–340.
107. 107 Ling, H., O'Sullivan, S.S., Holton, J.L., et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 133:Pt 7 (2010), 2045–2057.
108. 108 Hassan, A., Whitwell, J.L., Boeve, B.F., et al. Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord 16:3 (2010), 208–214.
109. 109 Kertesz, A., Davidson, W., McCabe, P., et al. Primary progressive aphasia: diagnosis, varieties, evolution. J Int Neuropsychol Soc 9:5 (2003), 710–719.
110. 110 Kertesz, A., McMonagle, P., Blair, M., et al. The evolution and pathology of frontotemporal dementia. Brain 128:Pt 9 (2005), 1996–2005.
111. 111 Wadia, P.M., Lang, A.E., The many faces of corticobasal degeneration. Parkinsonism Relat Disord 13:Suppl 3 (2007), S336–S340.
112. 112 Myers, A.J., Pittman, A.M., Zhao, A.S., et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 25:3 (2007), 561–570.
113. 113 Rabinovici, G.D., Rosen, H.J., Alkalay, A., et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77:23 (2011), 2034–2042.
114. 114 Whitwell, J.L., Jack, C.R. Jr., Boeve, B.F., et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 75:21 (2010), 1879–1887.
115. 115 Boxer, A.L., Geschwind, M.D., Belfor, N., et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 63:1 (2006), 81–86.
116. 116 Rankin, K.P., Mayo, M.C., Seeley, W.W., et al. Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease. J Mol Neurosci 45:3 (2011), 594–608.
117. 117 Steele, J.C., Richardson, J.C., Olszewski, J., Progressive supranuclear palsy. Arch Neurol 10:April (1964), 333–360.
118. 118 Chambers, C.B., Lee, J.M., Troncoso, J.C., et al. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 46:3 (1999), 325–332.
119. 119 Osaki, Y., Ben-Shlomo, Y., Lees, A.J., et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Mov Disord 19:2 (2004), 181–189.
120. 120 Hughes, A.J., Daniel, S.E., Ben-Shlomo, Y., et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:Pt 4 (2002), 861–870.
121. 121 Litvan, I., Agid, Y., Calne, D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1 (1996), 1–9.
122. 122 Donker Kaat, L., Boon, A.J., Kamphorst, W., et al. Frontal presentation in progressive supranuclear palsy. Neurology 69:8 (2007), 723–729.
123. 123 Williams, D.R., Lees, A.J., Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 8:3 (2009), 270–279.
124. 124 Kertesz, A., McMonagle, P., Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy. J Neurol Sci 289:1–2 (2010), 138–143.
125. 125 Lu, C.H., Macdonald-Wallis, C., Gray, E., et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84:22 (2015), 2247–2257.
126. 126 Meeter, L.H., Dopper, E.G., Jiskoot, L.C., et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3:8 (2016), 623–636.
127. 127 Rohrer, J.D., Woollacott, I.O., Dick, K.M., et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87:13 (2016), 1329–1336.
128. 128 Rojas, J.C., Karydas, A., Bang, J., et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:3 (2016), 216–225.
129. 129 Kim, Y.E., Kang, S.Y., Ma, H.I., et al. A visual rating scale for the hummingbird sign with adjustable diagnostic validity. J Parkinsons Dis 5:3 (2015), 605–612.
130. 130 Mackenzie, I.R., Neumann, M., Bigio, E.H., et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 117:1 (2009), 15–18.
131. 131 Mackenzie, I.R., Neumann, M., Bigio, E.H., et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 119:1 (2010), 1–4.
132. 132 Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., et al. A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72:5 (1975), 1858–1862.
133. 133 Mandelkow, E.M., Mandelkow, E., Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med, 2(7), 2012, a006247.
134. 134 Jenkins, S.M., Johnson, G.V., Tau complexes with phospholipase C-gamma in situ. Neuroreport 9:1 (1998), 67–71.
135. 135 Leugers, C.J., Lee, G., Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem 285:25 (2010), 19125–19134.
136. 136 Morris, M., Maeda, S., Vossel, K., et al. The many faces of tau. Neuron 70:3 (2011), 410–426.
137. 137 Clark, L.N., Poorkaj, P., Wszolek, Z., et al. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A 95:22 (1998), 13103–13107.
138. 138 Hutton, M., Lendon, C.L., Rizzu, P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:6686 (1998), 702–705.
139. 139 Poorkaj, P., Bird, T.D., Wijsman, E., et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 43:6 (1998), 815–825.
140. 140 Spillantini, M.G., Murrell, J.R., Goedert, M., et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 95:13 (1998), 7737–7741.
141. 141 Wilhelmsen, K.C., Lynch, T., Pavlou, E., et al. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 55:6 (1994), 1159–1165.
142. 142 Ghetti, B., Oblak, A.L., Boeve, B.F., et al. Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 41:1 (2015), 24–46.
143. 143 Zhukareva, V., Mann, D., Pickering-Brown, S., et al. Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol 51:6 (2002), 730–739.
144. 144 Tacik, P., DeTure, M., Hinkle, K.M., et al. A novel tau mutation in exon 12, p.Q336H, causes hereditary pick disease. J Neuropathol Exp Neurol 74:11 (2015), 1042–1052.
145. 145 Graff-Radford, N.R., Damasio, A.R., Hyman, B.T., et al. Progressive aphasia in a patient with Pick's disease: a neuropsychological, radiologic, and anatomic study. Neurology 40 (1990), 620–626.
146. 146 Irwin, D.J., Tauopathies as clinicopathological entities. Parkinsonism Relat Disord 22:Suppl 1 (2016), S29–S33.
147. 147 Irwin, D.J., Brettschneider, J., McMillan, C.T., et al. Deep clinical and neuropathological phenotyping of Pick disease. Ann Neurol 79:2 (2016), 272–287.
148. 148 Dickson, D.W., Bergeron, C., Chin, S.S., et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 61:11 (2002), 935–946.
149. 149 Josephs, K.A., Hodges, J.R., Snowden, J.S., et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol 122:2 (2011), 137–153.
150. 150 Litvan, I., Hauw, J.J., Bartko, J.J., et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55:1 (1996), 97–105.
151. 151 Dickson D. Neurodegeneration: the molecular pathology of dementia and movement disorders. 2nd edition. Chichester, West Sussex: Wiley-Blackwell; 2011. p. 1. online resource (xvii, 477 pages).
152. 152 Lee, V.M., Goedert, M., Trojanowski, J.Q., Neurodegenerative tauopathies. Annu Rev Neurosci 24 (2001), 1121–1159.
153. 153 Bigio, E.H., Brown, D.F., White, C.L., Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol 58:4 (1999), 359–364.
154. 154 Feany, M.B., Dickson, D.W., Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 40:2 (1996), 139–148.
155. 155 Ahmed, Z., Bigio, E.H., Budka, H., et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol 126:4 (2013), 537–544.
156. 156 Fujino, Y., Wang, D.S., Thomas, N., et al. Increased frequency of argyrophilic grain disease in Alzheimer disease with 4R tau-specific immunohistochemistry. J Neuropathol Exp Neurol 64:3 (2005), 209–214.
157. 157 Thal, D.R., Schultz, C., Botez, G., et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathol Appl Neurobiol 31:3 (2005), 270–279.
158. 158 Grinberg, L.T., Wang, X., Wang, C., et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol 125:4 (2013), 581–593.
159. 159 Ishihara, K., Araki, S., Ihori, N., et al. Argyrophilic grain disease presenting with frontotemporal dementia: a neuropsychological and pathological study of an autopsied case with presenile onset. Neuropathology 25:2 (2005), 165–170.
160. 160 Tsuchiya, K., Mitani, K., Arai, T., et al. Argyrophilic grain disease mimicking temporal Pick's disease: a clinical, radiological, and pathological study of an autopsy case with a clinical course of 15 years. Acta Neuropathol 102:2 (2001), 195–199.
161. 161 Baralle, M., Buratti, E., Baralle, F.E., The role of TDP-43 in the pathogenesis of ALS and FTLD. Biochem Soc Trans 41:6 (2013), 1536–1540.
162. 162 Polymenidou, M., Lagier-Tourenne, C., Hutt, K.R., et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14:4 (2011), 459–468.
163. 163 Buratti, E., Baralle, F.E., The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet 66 (2009), 1–34.
164. 164 Cairns, N.J., Neumann, M., Bigio, E.H., et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 171:1 (2007), 227–240.
165. 165 Mackenzie, I.R., The neuropathology of FTD associated With ALS. Alzheimer Dis Assoc Disord 21:4 (2007), S44–S49.
166. 166 Snowden, J.S., Adams, J., Harris, J., et al. Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations. Amyotroph Lateral Scler Frontotemporal Degener 16:7–8 (2015), 497–505.
167. 167 Cairns, N.J., Bigio, E.H., Mackenzie, I.R., et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 114:1 (2007), 5–22.
168. 168 Baloh, R.H., How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?. Curr Opin Neurol 25:6 (2012), 701–707.
169. 169 Mackenzie, I.R., Neumann, M., FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res 1462 (2012), 40–43.
170. 170 Munoz, D.G., Neumann, M., Kusaka, H., et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118:5 (2009), 617–627.
171. 171 Mackenzie, I.R., Munoz, D.G., Kusaka, H., et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol 121:2 (2011), 207–218.
172. 172 Neumann, M., Roeber, S., Kretzschmar, H.A., et al. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118:5 (2009), 605–616.
173. 173 Lee, E.B., Russ, J., Jung, H., et al. Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U. Acta Neuropathol Commun 1:9 (2013), 1–11.
174. 174 Holm, I.E., Isaacs, A.M., Mackenzie, I.R., Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Acta Neuropathol 118:5 (2009), 719–720.
175. 175 Skibinski, G., Parkinson, N.J., Brown, J.M., et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37:8 (2005), 806–808.
176. 176 Chow, T.W., Miller, B.L., Hayashi, V.N., et al. Inheritance of frontotemporal dementia. Arch Neurol 56:7 (1999), 817–822.
177. 177 Malamud, N., Waggoner, R.W., Geneaologic and clinicopathologic study of Pick's disease. Arch Neur Psych 50:3 (1943), 288–303.
178. 178 Sjogren, H., Alzheimer's disease-Pick's disease; a clinical analysis of 72 cases. Acta psychiatrica et neurologica Scandinavica. Supplementum(74), 1951, 189–192.
179. 179 Wilhelmsen, K.C., Lynch, T., Pavlou, E., et al. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Genet 55 (1994), 1159–1165.
180. 180 Grover, A., Houlden, H., Baker, M., et al. 5’ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem 274:21 (1999), 15134–15143.
181. 181 Rohrer, J.D., Warren, J.D., Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol 24:6 (2011), 542–549.
182. 182 Yasuda, M., Nakamura, Y., Kawamata, T., et al. Phenotypic heterogeneity within a new family with the MAPT p301s mutation. Ann Neurol 58:6 (2005), 920–928.
183. 183 Whitwell, J.L., Jack, C.R. Jr., Boeve, B.F., et al. Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology 72:9 (2009), 813–820.
184. 184 Conrad, C., Andreadis, A., Trojanowski, J.Q., et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy [see comments]. Ann Neurol 41:2 (1997), 277–281.
185. 185 Coppola, G., Chinnathambi, S., Lee, J.J., et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 21:15 (2012), 3500–3512.
186. 186 Baker, M., Mackenzie, I.R., Pickering-Brown, S.M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442:7105 (2006), 916–919.
187. 187 Cruts, M., Gijselinck, I., van der Zee, J., et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442:7105 (2006), 920–924.
188. 188 Petkau, T.L., Leavitt, B.R., Progranulin in neurodegenerative disease. Trends Neurosci 37:7 (2014), 388–398.
189. 189 Ward, M.E., Miller, B.L., Potential mechanisms of progranulin-deficient FTLD. J Mol Neurosci 45:3 (2011), 574–582.
190. 190 Coppola, G., Karydas, A., Rademakers, R., et al. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 64:1 (2008), 92–96.
191. 191 Van Damme, P., Van Hoecke, A., Lambrechts, D., et al. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181:1 (2008), 37–41.
192. 192 Mackenzie, I.R., The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathol 114:1 (2007), 49–54.
193. 193 Le Ber, I., Camuzat, A., Hannequin, D., et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 131:Pt 3 (2008), 732–746.
194. 194 van Swieten, J.C., Heutink, P., Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol 7:10 (2008), 965–974.
195. 195 Smith, K.R., Damiano, J., Franceschetti, S., et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am J Hum Genet 90:6 (2012), 1102–1107.
196. 196 Mann, D.M., Dipeptide repeat protein toxicity in frontotemporal lobar degeneration and in motor neurone disease associated with expansions in C9ORF72—a cautionary note. Neurobiol Aging 36:2 (2015), 1224–1226.
197. 197 Mackenzie, I.R., Arzberger, T., Kremmer, E., et al. Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol 126:6 (2013), 859–879.
198. 198 Mackenzie, I.R., Neumann, M., Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem 138:Suppl 1 (2016), 54–70.
199. 199 Vatsavayai, S.C., Yoon, S.J., Gardner, R.C., et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain 139:Pt 12 (2016), 3202–3216.
200. 200 Baborie, A., Griffiths, T.D., Jaros, E., et al. Accumulation of dipeptide repeat proteins predates that of TDP-43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. Neuropathol Appl Neurobiol 41:5 (2015), 601–612.
201. 201 Proudfoot, M., Gutowski, N.J., Edbauer, D., et al. Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathol 127:3 (2014), 451–458.
202. 202 Boeve, B.F., Boylan, K.B., Graff-Radford, N.R., et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135:Pt 3 (2012), 765–783.
203. 203 Sha, S.J., Takada, L.T., Rankin, K.P., et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology 79:10 (2012), 1002–1011.
204. 204 Whitwell, J.L., Weigand, S.D., Boeve, B.F., et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 135:Pt 3 (2012), 794–806.
205. 205 Lee, S.E., Khazenzon, A.M., Trujillo, A.J., et al. Altered network connectivity in frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Brain 137:Pt 11 (2014), 3047–3060.
206. 206 Neumann, M., Mackenzie, I.R., Cairns, N.J., et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 66:2 (2007), 152–157.
207. 207 Watts, G.D., Thomasova, D., Ramdeen, S.K., et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 72:5 (2007), 420–426.
208. 208 Johnson, J.O., Mandrioli, J., Benatar, M., et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 68:5 (2010), 857–864.
209. 209 Borghero, G., Floris, G., Cannas, A., et al. A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. Neurobiol Aging, 32(12), 2011, 2327.e1-e5.
210. 210 Kovacs, G.G., Murrell, J.R., Horvath, S., et al. TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord 24:12 (2009), 1843–1847.
211. 211 Mosca, L., Lunetta, C., Tarlarini, C., et al. Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject. Neurobiol Aging, 33(8), 2012, 1846.e1-e4.
212. 212 Freischmidt, A., Wieland, T., Richter, B., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 18:5 (2015), 631–636.
213. 213 Pottier, C., Bieniek, K.F., Finch, N., et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol 130:1 (2015), 77–92.
214. 214 Pottier, C., Ravenscroft, T.A., Sanchez-Contreras, M., et al. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem 138:Suppl 1 (2016), 32–53.
215. 215 Fecto, F., Yan, J., Vemula, S.P., et al. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 68:11 (2011), 1440–1446.
216. 216 Deng, H.X., Chen, W., Hong, S.T., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477:7363 (2011), 211–215.
217. 217 Narvid, J., Gorno-Tempini, M.L., Slavotinek, A., et al. Of brain and bone: the unusual case of Dr. A. Neurocase 15:3 (2009), 190–205.
218. 218 Kimura, T., Takamatsu, J., Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int 13:2 (2013), 506–507.
219. 219 Mendez, M.F., Shapira, J.S., McMurtray, A., et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 15:1 (2007), 84–87.
220. 220 Boxer, A.L., Knopman, D.S., Kaufer, D.I., et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 12:2 (2013), 149–156.
221. 221 Vercelletto, M., Boutoleau-Bretonniere, C., Volteau, C., et al., French research network on frontotemporal, dementia. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 23:4 (2011), 749–759.
222. 222 Herrmann, N., Black, S.E., Chow, T., et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 20:9 (2012), 789–797.
223. 223 Ikeda, M., Shigenobu, K., Fukuhara, R., et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 17:3 (2004), 117–121.
224. 224 Mendez, M.F., Shapira, J.S., Miller, B.L., Stereotypical movements and frontotemporal dementia. Mov Disord 20:6 (2005), 742–745.
225. 225 Swartz, J.R., Miller, B.L., Lesser, I.M., et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 58:5 (1997), 212–216.
226. 226 Lebert, F., Stekke, W., Hasenbroekx, C., et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 17:4 (2004), 355–359.
227. 227 Pijnenburg, Y.A., Sampson, E.L., Harvey, R.J., et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry 18:1 (2003), 67–72.
228. 228 Chow, T.W., Mendez, M.F., Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 17:5 (2002), 267–272.
229. 229 Cruz, M., Marinho, V., Fontenelle, L.F., et al. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol 21:2 (2008), 104–106.
230. 230 Finger, E.C., New potential therapeutic approaches in frontotemporal dementia: oxytocin, vasopressin, and social cognition. J Mol Neurosci 45:3 (2011), 696–701.
231. 231 Jesso, S., Morlog, D., Ross, S., et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain 134:Pt 9 (2011), 2493–2501.
232. 232 Merrilees, J., A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 21:4 (2007), S64–S691.
233. 233 Cheng, S.T., Chow, P.K., Song, Y.Q., et al. Mental and physical activities delay cognitive decline in older persons with dementia. Am J Geriatr Psychiatry 22:1 (2014), 63–74.
234. 234 Kortte, K.B., Rogalski, E.J., Behavioural interventions for enhancing life participation in behavioural variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatry 25:2 (2013), 237–245.
235. 235 Karakaya, T., Fusser, F., Prvulovic, D., et al. Treatment options for tauopathies. Curr Treat Options Neurol 14:2 (2012), 126–136.
236. 236 Schneider, A., Mandelkow, E., Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5:3 (2008), 443–457.
237. 237 Tsai, R.M., Boxer, A.L., Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem 138:Suppl 1 (2016), 211–221.
238. 238 Boxer, A.L., Gold, M., Huey, E., et al. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement 9:2 (2013), 176–188.
239. 239 Boxer, A.L., Gold, M., Huey, E., et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement 9:2 (2013), 189–198.
240. 240 Lagier-Tourenne, C., Baughn, M., Rigo, F., et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci U S A 110:47 (2013), E4530–E4539.